Aclaris Therapeutics (ACRS) Return on Capital Employed (2015 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Return on Capital Employed of 52.87% for Q1 2026, up 2229.0% year-over-year from 2.27% in Q1 2025, and up 3.53% quarter-over-quarter from 54.81% in Q4 2025.
Aclaris Therapeutics (ACRS) Return on Capital Employed (2015 - 2026) Analysis & Trends
Aclaris Therapeutics' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 52.87% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2229.0% year-over-year to 52.87%; the TTM figure through Mar 2026 stood at 52.87% (up 2229.0% YoY), while the FY2025 annual figure was 47.22%, up 3285.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 52.87%, up from 54.81% in the prior quarter.
- The five-year high for Return on Capital Employed was 30.28% in Q3 2024, with the low at 97.83% in Q3 2025.
- The 5-year median for Return on Capital Employed is 52.87% (2026), against an average of 55.03%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 3101 bps in 2024, then slumped 6755 bps in 2025.
- Aclaris Therapeutics' Return on Capital Employed stood at 37.57% in 2022, then tumbled by 46 bps to 55.03% in 2023, then slumped by 52 bps to 83.6% in 2024, then surged by 34 bps to 54.81% in 2025, then rose by 4 bps to 52.87% in 2026.
- Business Quant data shows ACRS's Return on Capital Employed at 52.87% in Q1 2026, 54.81% in Q4 2025, and 97.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | -53.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.62% |
| Mar 31, 2026 | -52.87% |
| Dec 31, 2025 | -54.81% |
| Sep 30, 2025 | -97.83% |
| Jun 30, 2025 | -87.92% |
| Mar 31, 2025 | -75.17% |
| Dec 31, 2024 | -83.60% |
| Sep 30, 2024 | -30.28% |
| Jun 30, 2024 | -44.38% |
| Mar 31, 2024 | -52.14% |
| Dec 31, 2023 | -55.03% |
| Sep 30, 2023 | -61.29% |
| Jun 30, 2023 | -53.22% |
| Mar 31, 2023 | -45.05% |
| Dec 31, 2022 | -37.57% |
| Sep 30, 2022 | -33.07% |
| Jun 30, 2022 | -35.20% |
| Mar 31, 2022 | -36.06% |
| Dec 31, 2021 | -38.27% |
| Sep 30, 2021 | -31.17% |